New advances in molecular approaches to head and neck squamous cell carcinoma

Anti-Cancer Drugs

Volumn 22, Issue 7, 2011, Pages 656-664

  Sahu, Nivedita ^a   Grandis, Jennifer Rubin ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

biomarker; epidermal growth factor receptor; head and neck squamous cell carcinoma; microarray; proteomics

Indexed keywords

ANGIOTENSINOGEN; APOLIPOPROTEIN A1; CARBOPLATIN; CETUXIMAB; CHLORIDE CHANNEL; CYTOKERATIN 17; CYTOKERATIN 2; CYTOKERATIN 4; EOTAXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE 2; KININOGEN; MESSENGER RNA; OSTEOPONTIN; PACLITAXEL; PROHIBITIN; SERINE PROTEINASE INHIBITOR; STAT3 PROTEIN; STEFIN A; STROMAL CELL DERIVED FACTOR 1ALPHA; UVOMORULIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; APOPTOSIS; BASE MISPAIRING; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA MICROARRAY; DNA REPAIR; DRUG RESPONSE; DRUG USE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FOCAL ADHESION; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE THERAPY; GENE VECTOR; GENETIC RISK; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMMUNE RESPONSE; IN VITRO STUDY; LYMPH NODE METASTASIS; MOLECULAR WEIGHT; PHOSPHORYLATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR GROWTH;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY;

EID: 79960463894     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834249ba     Document Type: Review

References (44)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Atkinson A, Colburn W, DeGruttola V, DeMets D, Downing G, Hoth D, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95. (Pubitemid 32225406)
3. Hensen EF, De Herdt MJ, Goeman JJ, Oosting J, Smit VT, Cornelisse CJ, et al. Gene-expression of metastasized versus non-metastasized primary head and neck squamous cell carcinomas: a pathway-based analysis. BMC Cancer 2008; 8:168.
4. Thurlow JK, Pena Murillo CL, Hunter KD, Buffa FM, Patiar S, Betts G, et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol 2010; 28:2881-2888.
5. Dumur CI, Ladd AC, Wright HV, Penberthy LT, Wilkinson DS, Powers CN, et al. Genes involved in radiation therapy response in head and neck cancers. Laryngoscope 2009; 119:91-101.
6. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006; 66:8210-8218. (Pubitemid 44299189)
7. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004; 5:489-500. (Pubitemid 38610250)
8. Wadsworth JT, Somers KD, Stack BC Jr, Cazares L, Malik G, Adam BL, et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004; 130:98-104. (Pubitemid 38095438)
9. Gourin CG, Xia ZS, Han Y, French AM, O'Rourke AK, Terris DJ, et al. Serum protein profile analysis in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132:390-397.
10. Gourin CG, Moretz WH III, Weinberger PM, Xia ZS, Liu Z, Terris DJ, et al. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2007; 133:1125-1130. (Pubitemid 350157025)
11. Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC Jr, et al. Differential capture of serum proteins for expression profiling and biomarker discovery in pre-and posttreatment head and neck cancer samples. Laryngoscope 2008; 118:61-68.
12. Gourin CG, Zhi W, Adam BL. Proteomic identification of serum biomarkers for head and neck cancer surveillance. Laryngoscope 2009; 119:1291-1302.
13. Merkley MA, Weinberger PM, Jackson LL, Podolsky RH, Lee JR, Dynan WS. 2D-DIGE proteomic characterization of head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2009; 141:626-632.
14. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Datta Gupta S, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 2008; 7:1162-1173. (Pubitemid 351943962)
15. Roesch-Ely M, Leipold A, Nees M, Holzinger D, Dietz A, Flechtenmacher C, et al. Proteomic analysis of field cancerization in pharynx and oesophagus: a prospective pilot study. J Pathol 2010; 221:462-470.
16. Patel V, Hood BL, Molinolo AA, Lee NH, Conrads TP, Braisted JC, et al. Proteomic analysis of laser-captured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression. Clin Cancer Res 2008; 14:1002-1014. (Pubitemid 351302545)
17. Toyoshima T, Vairaktaris E, Nkenke E, Schlegel KA, Friedrich WN, Ries J. Cytokeratin 17 mRNA expression has potential for diagnostic marker of oral squamous cell carcinoma. J Cancer Res Clin Oncol 2008; 134:515-521.
18. Pich A, Chiusa L, Navone R. Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol 2004; 15:1319-1329. (Pubitemid 39295019)
19. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C, et al. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol 2005; 7:837-843. (Pubitemid 41079057)
20. Liaudet-Coopman E, Beaujouin M, Derocq D, Garcia M, Glondu-Lassis M, Laurent-Matha V, et al. Cathepsin D: newly discovered functions of a long¬standing aspartic protease in cancer and apoptosis. Cancer Lett 2006; 237:167-179. (Pubitemid 43777078)
21. Grandis JR, Tweardy D. Elevated levels of transforming growth factor a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584. (Pubitemid 23229640)
22. Grandis JR, Melhem M, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824-832. (Pubitemid 28280548)
23. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62:7350-7356. (Pubitemid 36025259)
24. Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11:5856-5862. (Pubitemid 41170313)
25. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170-4176. (Pubitemid 46622295)
26. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. (Pubitemid 43209104)
27. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-1127.
28. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646-8654. (Pubitemid 46211507)
29. Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, et al. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 2009; 27:1235-1242.
30. Farhadieh RD, Salardini A, Rees CG, Russell PJ, Yang JL, Smee R. Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. Ann Surg Oncol 2009; 16:2888-2894.
31. Hama T, Yuza Y, Saito Y, O-uchi J, Kondo S, Okabe M, et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 2009; 14:900-908.
32. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. PNAS 2000; 97:4227-4232. (Pubitemid 30226115)
33. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, Azuma K, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002; 62:3351-3355. (Pubitemid 34651376)
34. Seethala RR, Gooding WE, Handler PN, Collins B, Zhang Q, Siegfried JM, et al. Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res 2008; 14:1303-1309. (Pubitemid 351413908)
35. Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, et al. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res 2010; 16:2427-2434.
36. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. PNAS 2003; 100:4138-4143. (Pubitemid 36418170)
37. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005; 24:970-979. (Pubitemid 40313874)
38. Marsit CJ, Posner MR, McClean MD, Kelsey KT. Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma. Cancer 2008; 113:1566-1571.
39. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008; 113:750-757.
40. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, et al. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 2010; 9:1755-1763.
41. Pattje WJ, Schuuring E, Mastik MF, Slagter-Menkema L, Schrijvers ML, Alessi S, et al. The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer. Br J Cancer 2010; 102:1778-1785.
42. Bandoh N, Ogino T, Katayama A, Takahara M, Katada A, Hayashi T, et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep 2010; 23:933-939.
43. De Koning PJ, Bovenschen N, Leusink FK, Broekhuizen R, Quadir R, Van Gemert JT, et al. Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome. Int J Cancer 2009; 125:1542-1550.
44. Ayoub C, Wasylyk C, Li Y, Thomas E, Marisa L, Robé A, et al. ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines. Br J Cancer 2010; 103:715-726.